GlassScriptPhysician profile
James L Liu
NPI 1730549882
$3,024.98
in general payments reported to CMS, 2019-2025
30 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $31.20 · 2021: $59.18 · 2022: $149 · 2023: $1,429 · 2024: $679 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,975 · Travel and Lodging: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,974.66 |
| Travel and Lodging | $810.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,436.26 | 2021-2025 | Titan, Porges Coloplast |
| Medtronic, INC. | $323.33 | 2024-2025 | Interstim, Altaviva |
| Boston Scientific Corporation | $287.47 | 2020-2023 | Lithovue |
| Sumitomo Pharma America, INC. | $150.83 | 2023-2025 | Orgovyx, Gemtesa |
| Abbvie INC. | $80.07 | 2024-2025 | |
| Urogen Pharma, INC. | $51.18 | 2024-2025 | |
| Endo USA, INC. | $49.67 | 2024-2025 | Xiaflex |
| Merck Sharp & Dohme LLC | $48.02 | 2024 | Keytruda |
| Astellas Pharma US INC | $45.16 | 2024-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $43.46 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.25 | 2024-2025 | |
| Laborie Medical Technologies Corp. | $42.04 | 2025 | |
| Blue Earth Diagnostics | $40.23 | 2023-2024 | |
| Telix Pharmaceuticals | $34.70 | 2023-2025 | Illuccix |
| Myriad Genetic Laboratories, INC. | $32.28 | 2024 | Prolaris |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $31.41 | 2024 | Arista Ah Flexitip |
| Olympus America INC. | $25.43 | 2023 | Itind System |
| Verity Pharmaceuticals INC. | $24.83 | 2025 | Tlando |
| 180 Medical, INC. | $24.54 | 2023 | |
| Dendreon Pharmaceuticals LLC | $23.68 | 2024 | Provenge |
| Endo Pharmaceuticals INC. | $23.14 | 2024 | Xiaflex |
| Astrazeneca Pharmaceuticals LP | $21.53 | 2025 | Lynparza |
| Calyxo, INC. | $21.32 | 2025 | Cvac Aspiration System |
| Mindray Ds USA, INC. | $20.34 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.11 | 2025 | |
| Convatec INC. | $19.71 | 2024 | |
| Immunitybio, INC. | $17.92 | 2024 | |
| Depuy Synthes Sales INC. | $17.12 | 2020 | |
| Ethicon US, LLC | $13.76 | 2022 | |
| Innovation Technologies INC | $13.19 | 2024 | Irrisept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.